A Study Evaluating The Combination of Immunotherapy With Radiotherapy in Non-Small Cell Lung Cancer

Current clinical trials testing the combination of immunotherapy with radiotherapy.

Trial Details

NCT ID
NCT07603856
Phase
PHASE2
Sponsor
University of Chicago
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Investigator Choice Immunotherapy (for example: pembrolizumab, cemiplimab, durvalumab, ipilimumab plus nivolumab)
  • Investigator Choice Chemotherapy (for example docetaxel with or without ramucirumab, gemcitabine, or other National Comprehensive Cancer Network (NCCN)-recommended treatments)
  • Ablative Hypofractionated Radiotherapy
Locations (sample)
  • Chicago, Illinois, United States|41.85003,-87.65005

Key Eligibility Criteria

  • Disease-Related Criteria
  • Patients must have histologically or cytologically confirmed metastatic or recurrent non-small cell lung cancer (NSCLC) with progression on prior i…
  • The patient's disease is eligible for SOC treatment with immunotherapy or chemotherapy.
  • Patients must have measurable disease per RECIST v1.1, defined as at least one lesion that can be accurately measured in at least one dimension wit…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →